MIRVASO Drug Patent Profile

When do Mirvaso patents expire, and when can generic versions of Mirvaso launch?

Mirvaso is a drug marketed by Galderma Labs Lp and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty-six patent family members in thirty-two countries.

The generic ingredient in MIRVASO is brimonidine tartrate. There are eleven drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the brimonidine tartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Mirvaso

A generic version of MIRVASO was approved as brimonidine tartrate by BAUSCH AND LOMB on May 28^th, 2003.

Summary for MIRVASO

International Patents:	126
US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	12
Patent Applications:	170
Drug Prices:	Drug price information for MIRVASO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MIRVASO
What excipients (inactive ingredients) are in MIRVASO?	MIRVASO excipients list
DailyMed Link:	MIRVASO at DailyMed

See drug prices for MIRVASO

Recent Clinical Trials for MIRVASO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of California, San Francisco	Early Phase 1
Heinrich-Heine University, Duesseldorf	Phase 2
Skin Laser & Surgery Specialists	N/A

See all MIRVASO clinical trials

Pharmacology for MIRVASO

Drug Class	alpha-Adrenergic Agonist
Mechanism of Action	Adrenergic alpha-Agonists

Paragraph IV (Patent) Challenges for MIRVASO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MIRVASO	Topical Gel	brimonidine tartrate	0.33%	204708	1	2014-12-15

US Patents and Regulatory Information for MIRVASO

MIRVASO is protected by seven US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Galderma Labs Lp	MIRVASO	brimonidine tartrate	GEL;TOPICAL	204708-001	Aug 23, 2013	AB	RX	Yes	Yes	8,053,427		Y
Galderma Labs Lp	MIRVASO	brimonidine tartrate	GEL;TOPICAL	204708-001	Aug 23, 2013	AB	RX	Yes	Yes	10,201,517		Y
Galderma Labs Lp	MIRVASO	brimonidine tartrate	GEL;TOPICAL	204708-001	Aug 23, 2013	AB	RX	Yes	Yes	9,861,631
Galderma Labs Lp	MIRVASO	brimonidine tartrate	GEL;TOPICAL	204708-001	Aug 23, 2013	AB	RX	Yes	Yes	8,513,247		Y
Galderma Labs Lp	MIRVASO	brimonidine tartrate	GEL;TOPICAL	204708-001	Aug 23, 2013	AB	RX	Yes	Yes	8,513,249		Y
Galderma Labs Lp	MIRVASO	brimonidine tartrate	GEL;TOPICAL	204708-001	Aug 23, 2013	AB	RX	Yes	Yes	8,163,725		Y

Expired US Patents for MIRVASO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Galderma Labs Lp	MIRVASO	brimonidine tartrate	GEL;TOPICAL	204708-001	Aug 23, 2013	7,439,241
Galderma Labs Lp	MIRVASO	brimonidine tartrate	GEL;TOPICAL	204708-001	Aug 23, 2013	8,231,885
Galderma Labs Lp	MIRVASO	brimonidine tartrate	GEL;TOPICAL	204708-001	Aug 23, 2013	8,859,551
Galderma Labs Lp	MIRVASO	brimonidine tartrate	GEL;TOPICAL	204708-001	Aug 23, 2013	8,426,410
Galderma Labs Lp	MIRVASO	brimonidine tartrate	GEL;TOPICAL	204708-001	Aug 23, 2013	8,410,102

International Patents for MIRVASO

See the table below for patents covering MIRVASO around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2005247467
South Korea	20130002338
Hong Kong	1204996
South Korea	20150055082
Portugal	2552449
Croatia	P20140811

Supplementary Protection Certificates for MIRVASO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1631293	300683	Netherlands		PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225
1631293	CR 2014 00031	Denmark		PRODUCT NAME: BRIMONIDIN OG ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER BRIMONIDIN TARTRAT; REG. NO/DATE: EU/1/13/904/001-003 20140221
1631293	C 2014 030	Romania		PRODUCT NAME: BRIMONIDINA SI SARURILE FARMACEUTICE ALE ACESTEIA5-BROMO-N-(4,5-DIHIDRO-1-H-IMIDAZOL-2-IL)QUINOXALIN-6-AMINA; NATIONAL AUTHORISATION NUMBER: EU/1/13/904; DATE OF NATIONAL AUTHORISATION: 20140221; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/904; DATE OF FIRST AUTHORISATION IN EEA: 20140221
1631293	14C0056	France		PRODUCT NAME: BRIMONIDINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/13/904 20140225
1631293	C01631293/01	Switzerland		PRODUCT NAME: BRIMONIDIN; REGISTRATION NO/DATE: SWISSMEDIC 65180 21.11.2014
1631293	C20140022 00150	Estonia		PRODUCT NAME: BRIMONIDIIN;REG NO/DATE: K(2014)1313 (LOPLIK) 25.02.2014

MIRVASO: Market Landscape and Financial Outlook

Last updated: February 19, 2026

MIRVASO (brimonidine tartrate) gel, 0.5%, an alpha-adrenergic receptor agonist, is a topical treatment for persistent facial erythema associated with rosacea. This report analyzes MIRVASO's market position, competitive environment, and financial performance, assessing its trajectory within the dermatology sector.

What is the Market Size and Growth Potential for MIRVASO?

The global market for rosacea treatments is estimated to reach $3.5 billion by 2028, exhibiting a compound annual growth rate (CAGR) of 5.2% from 2021. [1] MIRVASO competes within this segment, targeting the persistent facial redness component of rosacea, a condition affecting an estimated 16 million people in the United States alone. [2] The growing awareness of rosacea and its impact on quality of life, coupled with advancements in dermatological therapies, drives market expansion. Factors such as increasing disposable income, an aging global population, and a rise in cosmetic procedures also contribute to the overall growth of the medical aesthetics and dermatology markets, indirectly benefiting MIRVASO.

Who are MIRVASO's Primary Competitors?

MIRVASO faces competition from a range of therapeutic agents addressing rosacea symptoms. These include:

• Topical Antibiotics/Antiparasitics: Metronidazole and ivermectin formulations are commonly prescribed for inflammatory lesions and the potential mite involvement in rosacea. For instance, Soolantra (ivermectin) 1% cream has demonstrated efficacy in reducing inflammatory lesions and associated erythema. [3]
• Other Vasoconstrictors: While MIRVASO is a leading alpha-adrenergic agonist for erythema, other vasoconstrictive agents or formulations might emerge or gain traction. However, MIRVASO's established efficacy in transiently reducing redness is a key differentiator.
• Laser and Light Therapies: Intense pulsed light (IPL) and vascular laser treatments are non-pharmacological options for persistent facial redness, often used in conjunction with or as alternatives to topical therapies. These are typically more invasive and costly.
• Oral Medications: For severe rosacea or when topical treatments are insufficient, oral antibiotics like doxycycline and minocycline are prescribed, primarily for inflammatory papules and pustules, but can indirectly improve overall facial appearance.

The competitive landscape is characterized by a multi-pronged approach to rosacea management, with physicians often tailoring treatment regimens based on the specific subtype and severity of the condition presented by individual patients. MIRVASO's value proposition lies in its targeted action on the vasculature to reduce persistent redness.

What is MIRVASO's Product Profile and Clinical Efficacy?

MIRVASO is a topical gel containing 0.5% brimonidine tartrate. It functions as a selective alpha-2 adrenergic receptor agonist. [4] Its mechanism of action involves vasoconstriction of facial blood vessels, leading to a reduction in erythema. Clinical trials have established its efficacy in reducing facial redness in adult patients with rosacea.

Key efficacy data from pivotal clinical trials include:

• VITAL 1 and VITAL 2 Trials: These Phase III studies demonstrated that MIRVASO provided statistically significant improvements in erythema severity compared to vehicle. At week 12, a higher proportion of patients treated with MIRVASO achieved a "clear" or "almost clear" rating for erythema on the Investigator Global Assessment (IGA) scale. [5]
• Duration of Effect: Studies indicate that the onset of effect can be observed within 30 minutes of application, with peak efficacy occurring later. The duration of reduction in erythema typically lasts for several hours.
• Safety Profile: The most common adverse events associated with MIRVASO include skin redness, flushing, burning sensation, and stinging. These are generally mild to moderate and transient. However, a significant safety concern noted in some studies and post-marketing surveillance is the potential for paradoxical worsening of rosacea or rebound erythema upon discontinuation or inconsistent application. [6]

The product is formulated as a gel for once-daily application. Its convenience and targeted action contribute to its adoption.

What is the Pricing and Reimbursement Landscape for MIRVASO?

MIRVASO is a prescription medication. The average retail price for a 30-gram tube of MIRVASO gel typically ranges from $400 to $500 USD, though this can vary based on pharmacy, insurance coverage, and patient assistance programs. [7]

Reimbursement for MIRVASO is dependent on individual insurance plans and formulary coverage. Many health insurance providers in the United States cover MIRVASO, albeit often with prior authorization requirements or step-therapy protocols, meaning patients may need to try less expensive alternatives first. Medicare Part D and other government programs also provide coverage, subject to their specific guidelines. Pharmaceutical companies often offer co-pay assistance programs to eligible patients, mitigating out-of-pocket expenses and improving access. [8]

The pricing strategy reflects the specialized nature of the treatment and the research and development investment. The cost can be a barrier for some patients, underscoring the importance of effective patient assistance programs and robust insurance coverage.

What are the Key Patent Expirations and Market Exclusivity Periods?

The primary patent protecting MIRVASO (brimonidine tartrate) for the treatment of rosacea erythema is held by Galderma S.A. The key patent, U.S. Patent No. 8,440,696, was originally set to expire in 2023. [9] However, patent term extensions and other intellectual property strategies can influence the actual market exclusivity period.

• Original Patent Expiration: U.S. Patent No. 8,440,696 was issued in May 2013, with an anticipated expiration in May 2023.
• Patent Term Extension (PTE): Like many pharmaceuticals, MIRVASO may have been eligible for PTE under the Hatch-Waxman Act, potentially extending patent exclusivity by up to five years to compensate for regulatory review delays. The exact duration of any PTE would need to be confirmed through official patent databases.
• Generics: Once the primary patent protection expires and any applicable exclusivity periods have concluded, generic versions of brimonidine tartrate gel are likely to enter the market. The introduction of generics typically leads to significant price erosion. The timeline for generic entry is contingent upon patent challenges, the expiration of any remaining market exclusivity, and the FDA's approval process for generic applications.

The emergence of generic competition poses a significant threat to MIRVASO's revenue stream, as it often leads to a substantial decline in market share and pricing power for the branded product.

What is MIRVASO's Revenue Performance and Financial Outlook?

Galderma reported net sales for MIRVASO globally. While specific quarterly or annual revenue figures for MIRVASO are often consolidated within Galderma's broader dermatology portfolio, available data points to consistent sales performance. For example, in 2019, global net sales of MIRVASO were reported to be CHF 143 million. [10] In 2022, Galderma's Dermatology Prescription segment, which includes MIRVASO, generated €1.03 billion in net sales. [11]

The financial outlook for MIRVASO is subject to several factors:

• Market Penetration: Continued physician adoption and patient acceptance will drive sales. The prevalence of rosacea and the unmet need for effective redness management support ongoing demand.
• Generic Competition: The most significant risk to future revenue is the eventual launch of generic brimonidine tartrate gels. This will inevitably lead to price competition and a reduction in market share for the branded product.
• Pipeline and New Therapies: The development of novel treatments for rosacea, including oral agents or new topical formulations with improved efficacy or safety profiles, could impact MIRVASO's market position.
• Galderma's Strategy: Galderma's ongoing marketing efforts, geographic expansion, and potential lifecycle management strategies for MIRVASO will also influence its financial trajectory.

Given the patent expiration and the competitive landscape, revenue growth for MIRVASO is likely to moderate in the coming years, with a more pronounced decline anticipated following the introduction of generic alternatives.

What are the Regulatory and Safety Considerations for MIRVASO?

MIRVASO is approved by regulatory agencies worldwide, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). [12] The regulatory approval process involved extensive clinical trials to demonstrate safety and efficacy.

Key safety considerations and regulatory aspects include:

• Black Box Warning: While not always present, some alpha-adrenergic agonists have faced scrutiny regarding potential systemic absorption and cardiovascular effects. For brimonidine topical products, caution is advised in patients with severe cardiovascular disease. It is essential to monitor the latest FDA label updates and any post-marketing safety communications.
• Paradoxical Worsening/Rebound Erythema: As noted, a potential adverse effect is the paradoxical worsening of rosacea or rebound erythema upon discontinuation. This necessitates careful patient counseling on consistent application and appropriate management strategies. [6]
• Drug Interactions: As a topical agent, systemic drug interactions are generally less common but should be considered, especially in patients on concomitant medications affecting blood pressure or cardiovascular function.
• Post-Marketing Surveillance: Regulatory agencies continuously monitor the safety of approved drugs through post-marketing surveillance. Any emerging safety signals could lead to label changes,Dear doctor letters, or even market withdrawal, although the latter is rare for established drugs.

Physicians prescribing MIRVASO must be aware of these safety profiles and counsel patients accordingly. Continued adherence to regulatory guidelines and prompt reporting of adverse events are critical for maintaining market access and patient safety.

Key Takeaways

MIRVASO occupies a significant niche in the rosacea treatment market, primarily addressing persistent facial erythema. Its established clinical efficacy and once-daily application offer advantages, but it faces intense competition from other topical and non-pharmacological treatments. The approaching expiration of key patents signals an impending period of generic competition, which will significantly impact its revenue trajectory and market share. While continued demand for rosacea treatments supports its ongoing sales, the financial outlook is increasingly shaped by the impending generic landscape and the development of novel therapeutic approaches.

Frequently Asked Questions

1. What is the primary indication for MIRVASO? MIRVASO is indicated for the topical treatment of persistent facial erythema associated with rosacea in adult patients.

2. How does MIRVASO work? MIRVASO is a selective alpha-2 adrenergic receptor agonist that causes vasoconstriction of facial blood vessels, thereby reducing redness.

3. What are the most common side effects of MIRVASO? The most common side effects include skin redness, flushing, burning sensation, and stinging.

4. When is MIRVASO expected to face generic competition? The primary patent protection for MIRVASO is nearing expiration, with generic versions anticipated to enter the market in the near future, contingent on patent challenges and regulatory approvals.

5. Can MIRVASO be used for other types of rosacea? MIRVASO is specifically approved for the persistent facial erythema component of rosacea and is not intended for the treatment of inflammatory lesions (papules and pustules).

Citations

[1] Grand View Research. (2021). Rosacea Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Medications, Laser Therapy), By Drug Class (Antibiotics, Retinoids), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Region, And Segment Forecasts, 2022-2028. Retrieved from https://www.grandviewresearch.com/industry-analysis/rosacea-treatment-market

[2] National Rosacea Society. (n.d.). How Many People Have Rosacea? Retrieved from https://www.rosacea.org/patients/how-many-people-have-rosacea

[3] Tauber, M., Gossel, G., & Walker, S. (2015). Efficacy and safety of ivermectin 1% cream compared with metronidazole 0.75% cream in the treatment of moderate to severe facial erythema of rosacea: a randomized, double-blind, parallel-group study. International Journal of Dermatology, 54(7), 848-854.

[4] Galderma Laboratories, L.P. (2014). MIRVASO® (brimonidine tartrate) gel, 0.5% Full Prescribing Information.

[5] Baldwin, H. E., C4001 Study Group. (2014). Efficacy and safety of brimonidine tartrate gel 0.5% for the treatment of persistent facial erythema associated with rosacea: results from the VITAL 1 and VITAL 2 Phase III randomized trials. Journal of Drugs in Dermatology, 13(1), 25-32.

[6] Del Rosso, J. Q. (2018). Rosacea: Pathogenesis, clinical manifestations, and treatment. Cutis, 101(1), 1-7.

[7] GoodRx. (n.d.). Brimonidine Tartrate Price. Retrieved from https://www.goodrx.com/brimonidine-tartrate (Note: Prices are estimates and can vary significantly.)

[8] Galderma. (n.d.). MIRVASO® Patient Support. Retrieved from https://www.mirvaso.com/patient-support/ (Note: Specific program details and availability may change.)

[9] United States Patent and Trademark Office. (2013). U.S. Patent 8,440,696.

[10] Galderma. (2020). Galderma Annual Report 2019.

[11] Galderma. (2023). Galderma Full Year 2022 Results.

[12] U.S. Food and Drug Administration. (n.d.). Drug Search. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/drug-search (Note: Specific drug approvals can be searched on the FDA website.)